interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Lutetium Lu-177 Vipivotide Tetraxetan

Generic competition · all medicines · read 12 November 2026

Is there a generic of Lutetium Lu-177 Vipivotide Tetraxetan, and who makes it?

Lutetium Lu-177 Vipivotide Tetraxetan appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Lutetium Lu-177 Vipivotide Tetraxetan1 dosage-form group in the Orange Book
0generic makers listed
  1. Lutetium Lu-177 Vipivotide Tetraxetan appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Solution, Intravenous

Brand listed, no generic listed as marketed

Brand listed as marketed: Pluvicto. No generic is listed as marketed.

20202025203020352040204501brand 2022data datePatent 11318121 listed to expire 15 August 2028Patent 10406240 listed to expire 15 August 2028Patent 11951190 listed to expire 12 November 2035Patent 10398791 listed to expire 23 March 2036Patent 12208102 listed to expire 18 September 2041Exclusivity NCE to 23 March 2027Exclusivity I-965 to 28 March 2028Exclusivity I-996 to 31 July 2029
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 23 March 2027Exclusivity NCE Pluvicto
  • 28 March 2028Exclusivity I-965 Pluvicto
  • 31 July 2029Exclusivity I-996 Pluvicto
  • 15 August 2028Patent 11318121 drug substance
  • 15 August 2028Patent 10406240 drug substance
  • 12 November 2035Patent 11951190
  • 23 March 2036Patent 10398791 drug substance
  • 18 September 2041Patent 12208102

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.